Stephen Harrison, MD, discusses how specialists can help educate PCPs on NAFLD, the importance of PCPs recognizing which individuals with NAFLD can progress to more severe liver disease, and more.
He discusses his session on endocrine pathways and therapeutic options for patients with nonalcoholic fatty liver disease, which he presented at Harvard University’s 21st Annual Symposium on NAFLD.
Dr Harrison discusses key takeaways for gastroenterologists and hepatologists about the management of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Dr Harrison highlights the importance of new treatment options for patients with nonalcoholic steatohepatitis, discusses findings from the REGENERATE clinical trial presented at the ACG 2019 Annual Meeting,...
He gives an overview of his session at our upcoming Cardiometabolic Risk Summit, which includes a discussion about non-alcoholic fatty liver disease, how fat affects the liver, and why patients (and...
Dr Loo and Dr Chen highlight the current management of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, obesity as a risk factor for the diseases, and more.
In this 13-minute podcast, Jonathan Stine, MD, from the Milton S. Hershey Medical Center at Pennsylvania State University, discusses his proof-of-concept study concerning the relationship of nonalcoholic...
